2nd Annual Oncology Biomarkers Congress
10 Oct 2012 - 11 Oct 2012 - Manchester, UK
The event will bring together key scientists whose expertise is focused on biomarkers, companion diagnostics, personalized medicine, safety studies, translational medicine and decision making in the oncology therapeutic area, from leading pharmaceutical, biotechnology, diagnostics, clinical research companies and academic institutions in the UK and Europe.
The global Oncology Biomarkers market is expected to grow from $4.1 billion in 2009 to $9.5 billion in 2014. The demand is increasing due to organizations trying to increase the success to failure rate of oncology drugs as well as the ability to trace the exact type of cancer and to be more specific with potential targets. Oncology biomarkers facilitate high-speed non-invasive cancer diagnosis and enhance screening and early cancer detection. The market offers high-growth opportunities with numerous initiatives to encourage biomarker-based cancer treatment.
This prestigious event provides a forum for practitioners and researchers to learn more about key solutions being provided to their industry, analysis of current technologies and their applications, network with their peers and address key industry concerns through a series of cutting edge conference presentations and interactive exhibition room in a professional yet relaxed environment.